After an earlier trial showed patients with elevated levels of a cardiac stress marker benefited from its cell therapy, the firm shifted focus to this subset.

On the heels of its acquisition by Ocuphire Pharma, Opus is planning next steps for its Leber congenital amaurosis type 5 ...

ACMG, NSGC, and others in the genetics community are monitoring whether the widely used online clinical genetics database ...

The benefits of early TAVR for patients with asymptomatic, severe aortic stenosis are consistent regardless of NT-proBNP or ...

The biotech firm closed an oversubscribed Series C funding round, proceeds from which it will use to advance ATSN-201 and its ...

NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) on Friday recommended that the National Health Service make AstraZeneca's AKT pathway inhibitor Truqap (capivasertib) with ...

The 2018 accelerated approval of Vitrakvi was converted to full approval based on results from three trials in adult and pediatric patients.

Researchers shared data at ACC from BioCardia's initial Phase III cell therapy trial, which the firm stopped enrolling based ...

The company expects early cohort data this year from the trial assessing the calpain-2-targeted antisense oligonucleotide therapy.

Patients at risk for heart disease experienced significant reductions in apolipoprotein B and LDL cholesterol levels on ...